Biorestorative therapies regains compliance with nasdaq listing rule 5250(c)(1); reports first quarter 2024 financial results

- significant yoy improvement in operating performance - - ends q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - melville, n.y., june 17, 2024 (globe newswire) -- biorestorative therapies, inc.
NDAQ Ratings Summary
NDAQ Quant Ranking